ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

被引：2
|
作者：
Hanamoto, Hitoshi
Morita, Yasuyoshi
Ichikawa, Motoshi
Nannya, Yasuhito
Shibayama, Hirohiko
Maeda, Yoshinobu
Hata, Tomoko
Miyamoto, Toshihiro
Kawabata, Hiroshi
Takeuchi, Kazuto
Tanaka, Hiroko
Kishimoto, Junji
Miyano, Satoru
Matsumura, Itaru
Ogawa, Seishi
Akashi, Koichi
Kanakura, Yuzuru
Mitani, Kinuko
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134483
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Multicenter phase II study of antimicrobial prophylaxis in low-risk patients undergoing distal gastrectomy for gastric cancer
    Imamura H.
    Furukawa H.
    Iijima S.
    Sugihara S.
    Tsujinaka T.
    Tsukuma H.
    Shimokawa T.
    Gastric Cancer, 2006, 9 (1) : 32 - 35
  • [22] Effect of phosphoinositide-phospholipase c beta1 monoallelic deletion in low-risk MDS patients treated with darbepoetin.
    Spadaro, P.
    Pitini, V.
    Arrigo, C.
    Ingemi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
    Villegas, A.
    Arrizabalaga, B.
    Fernandez-Lago, C.
    Castro, M.
    Mayans, J. R.
    Gonzalez-Porras, J. R.
    Duarte, R. F.
    Remacha, A. F.
    Luno, E.
    Gasquet, J. A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 951 - 960
  • [24] High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR)+/-G-CSF in Lower-Risk MDS: a Phase II Study
    Kelaidi, Charikleia
    Beyne-Rauzy, Odile
    Braun, Thorsten
    Cougou, Pierre
    Ades, Lionel
    Pillard, Fabien
    Lamberto, Christine
    Jernival, Tony
    Mortera, Edith
    Guerci, Agnes
    Choufi, B.
    Stamatoullas, Aspasia
    Slama, Borhane
    De Renzis, Benoit
    Ame, S.
    Ghandi, Damaj
    Boyer, Francoise
    Chaury, Marie-Pierre
    Legros, Laurence
    Cheze, Stephane
    Testu, Anna
    Gyan, Emmanuel
    Bene, Marie C.
    Rose, Christian
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2009, 114 (22) : 1467 - 1467
  • [25] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    BLOOD, 2017, 130
  • [26] Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis
    Tefferi, Ayalew
    Lasho, Terra L.
    Hanson, Curtis A.
    Ketterling, Rhett P.
    Gangat, Naseema
    Pardanani, Animesh
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (04) : 678 - 681
  • [27] The Association of ASXL1 and ZRSR2 Mutations with Response to the Combination of Alvocidib and 5-Azacytidine in Patients with High-risk myelodysplastic Syndromes
    Riabov, V
    Xu, Q.
    Schmitt, N.
    Streuer, A.
    Jann, J-C
    Wein, A.
    Altrock, E.
    Mehralivand, A.
    Nowak, V
    Weimer, N.
    Oblaender, J.
    Palme, I
    Jawhar, A.
    Darwich, A.
    Wuchter, P.
    Weiss, C.
    Metzgeroth, G.
    Foulks, J. M.
    Steiner, L.
    Jawhar, M.
    Hofmann, W-K
    Nowak, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 37 - 37
  • [28] Antithymocyte globulin (ATG) has limited efficacy in anemic patients with low-risk myelodysplastic syndrome (MDS): Results of a prematurely terminated phase IItrial.
    Steensma, DP
    Dispenzieri, A
    Schroeder, G
    Tefferi, A
    BLOOD, 2002, 100 (11) : 338B - 338B
  • [29] Cytogenetic monitoring of response and karyotype evolution in low-risk MDS patients treated in the LeMon5 study
    Shirneshan, K.
    Platzbecker, U.
    Nolte, F.
    Giagounidis, A.
    Goetze, K.
    Braulke, F.
    Schanz, J.
    Germing, U.
    Haase, D.
    ONKOLOGIE, 2013, 36 : 240 - 240
  • [30] ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG
    Paschka, Peter
    Schlenk, Richard F.
    Herzig, Julia
    Aulitzky, Teresa
    Gaidzik, Verena I.
    Bullinger, Lars
    Habdank, Marianne
    Corbacioglu, Andrea
    Spaeth, Daniela
    Koehne, Claus-Henning
    Kuendgen, Andrea
    von Lilienfeld-Toal, Marie
    Held, Gerhard
    Horst, Heinz A.
    Goetze, Katharina
    Bentz, Martin
    Krauter, Juergen
    Ganser, Arnold
    Doehner, Hartmut
    Doehner, Konstanze
    BLOOD, 2011, 118 (21) : 189 - 189
12345